Discounted Cash Flow (DCF) Analysis Levered
Onconova Therapeutics, Inc. (ONTX)
$1.34
-0.11 (-7.59%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.79 | 1.23 | 2.18 | 0.23 | 0.23 | 0.25 | 0.28 | 0.31 | 0.34 | 0.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -23.82 | -22.70 | -20.83 | -23.08 | -19.49 | -12.21 | -13.50 | -14.93 | -16.50 | -18.25 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | - | -0.06 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -23.82 | -22.70 | -20.89 | -23.09 | -19.50 | -12.22 | -13.51 | -14.94 | -16.52 | -18.26 |
Weighted Average Cost Of Capital
| Share price | $ 1.34 |
|---|---|
| Beta | 1.619 |
| Diluted Shares Outstanding | 16.83 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 10.405 |
| Total Debt | - |
| Total Equity | 22.56 |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.79 | 1.23 | 2.18 | 0.23 | 0.23 | 0.25 | 0.28 | 0.31 | 0.34 | 0.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.82 | -22.70 | -20.83 | -23.08 | -19.49 | -12.21 | -13.50 | -14.93 | -16.50 | -18.25 |
| Capital Expenditure | - | - | -0.06 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Free Cash Flow | -23.82 | -22.70 | -20.89 | -23.09 | -19.50 | -12.22 | -13.51 | -14.94 | -16.52 | -18.26 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -18.63 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -55.07 |
| Equity Value | - |
| Shares Outstanding | 16.83 |
| Equity Value Per Share | - |